|Videos|May 8, 2023
Closing Thoughts on the Future of mCRPC Treatment
Author(s)Andrew J. Armstrong, MD, Matthew Manning, MD
Matthew Manning, MD, and Andrew Armstrong, MD, discuss the remaining unmet needs in mCRPC, clinical trials and novel agents to look out for, and share practical advice for other clinicians treating patients with the disease.
Advertisement
Episodes in this series
Advertisement
Related to this article
Jason Hafron, MD, discusses the emotional, clinical, and financial burden of false positive cancer screening results and improved risk stratification.
Advertisement
Advertisement
Trending on OncLive
1
Ifinatamab Deruxtecan BLA Voluntarily Withdrawn in Previously Treated Extensive-Stage SCLC
2
Long-Term PERSEUS Data Confirm Durable PFS Benefit With D-VRd in Transplant-Eligible Newly Diagnosed Myeloma
3
Five Under 5: Top Oncology Videos for the Week of 9/20
4
China's NMPA Approves Pirtobrutinib Across CLL
5